Aripiprazole

證據等級: L5

預測適應症: 10 個

Aripiprazole: From Schizophrenia & Bipolar Disorder to Major Affective Disorder

One-Sentence Summary

Aripiprazole is an atypical antipsychotic originally developed for schizophrenia and bipolar disorder, acting as a dopamine D2/D3 partial agonist combined with serotonin 5-HT1A partial agonism and 5-HT2A antagonism. The TxGNN model predicts it may be effective for Major Affective Disorder (encompassing major depressive disorder and bipolar depression), with 50 clinical trials and 20 publications currently supporting this direction — placing evidence at the highest confidence tier, L1.

Quick Overview

Item	Content
Original Indication	Schizophrenia; Bipolar Disorder (established global approvals)
Predicted New Indication	Major Affective Disorder
TxGNN Prediction Score	99.62%
Evidence Level	L1
Taiwan Market Status	Not registered (未上市)
Number of NDAs	0 (Taiwan)
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Aripiprazole belongs to a third generation of atypical antipsychotics distinguished by dopamine system stabilization rather than full D2 receptor blockade. As a partial agonist at D2 and D3 receptors, it dampens hyperactive mesolimbic dopamine transmission (the source of psychotic symptoms) while simultaneously boosting hypoactive mesocortical dopamine signaling (critical for mood, motivation, and executive function). Concurrently, its partial agonism at 5-HT1A receptors and blockade of 5-HT2A receptors modulate serotonergic circuits in a manner that reinforces and extends the effects of conventional antidepressants — explaining its unique position as an augmentation agent rather than a replacement.

Major affective disorder — covering both major depressive disorder (MDD) and bipolar depression — involves dysregulation of precisely these dopaminergic and serotonergic systems. When a patient fails to respond adequately to SSRI or SNRI monotherapy, the residual dopaminergic deficit remains unaddressed; adding aripiprazole targets this gap directly. This mechanistic complementarity is why aripiprazole is effective specifically in treatment-resistant and partially responsive MDD populations, rather than as a first-line antidepressant.

This is not speculative repurposing. Aripiprazole has received US FDA approval as adjunctive treatment for MDD and for bipolar I disorder depressive episodes, supported by multiple large Phase 3 randomized controlled trials. The TxGNN prediction score of 99.62% aligns perfectly with an already well-validated clinical direction. The key repurposing question for this Evidence Pack is therefore not biological plausibility — that is firmly established — but rather the Taiwan-specific regulatory and access pathway.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00683852	Phase 3	Completed	225	Double-blind, placebo-controlled; directly assessed whether reduced-dose aripiprazole is effective as adjunctive treatment in MDD patients with inadequate antidepressant response — a core registration-level efficacy trial
NCT00095823	Phase 3	Completed	1,200	Large 14-week pivotal RCT; safety and efficacy of aripiprazole adjunctive to ongoing antidepressant in MDD — one of the primary registration trials supporting FDA approval
NCT00095758	Phase 3	Completed	1,200	Parallel large 14-week double-blind, placebo-controlled RCT; adjunctive aripiprazole in MDD — complementary registration trial, together with NCT00095823 providing n=2,400 pivotal dataset
NCT00876343	Phase 3	Completed	586	Placebo-controlled; examined efficacy and safety of aripiprazole vs placebo as adjunctive therapy with SSRI or SNRI in MDD patients
NCT00105196	Phase 3	Completed	349	14-week randomized double-blind placebo-controlled; aripiprazole as adjunct to assigned antidepressant in MDD patients with incomplete 8-week prospective antidepressant response
NCT00882362	Phase 3	Completed	155	Long-term (3+ year) adjunctive therapy with SSRI/SNRI; examined safety and sustained efficacy of extended aripiprazole use in MDD — key maintenance data
NCT07153406	Phase 3	Not Yet Recruiting	220	Active comparator trial: esketamine nasal spray vs aripiprazole augmentation in elderly treatment-resistant MDD (>60 years); will directly benchmark aripiprazole against an emerging therapy
NCT01429831	Phase 4	Completed	300	Taiwan real-world observational study; evaluates effectiveness and tolerability of aripiprazole augmentation specifically in Taiwan clinical practice for MDD patients with inadequate antidepressant response
NCT02918370	Phase 3	Completed	75	12-week randomized double-blind placebo-controlled; aripiprazole in bipolar I/II with comorbid alcohol use disorder in depressed or mixed phase — provides important comorbidity safety and efficacy data
NCT01284218	N/A	Completed	23,514	Large retrospective database study; compared healthcare utilization and costs between MDD patients on adjunctive aripiprazole vs other augmentation therapies — real-world economic evidence

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38669232	2024	Systematic Review & Meta-Analysis	PLoS One	First and largest meta-analysis of RCTs evaluating aripiprazole or bupropion augmentation and switching in TRD and MDD; head-to-head comparative efficacy and safety
34986373	2022	Systematic Review / Network Meta-Analysis	J Affect Disord	Network meta-analysis comparing augmentation agents in treatment-resistant depression; aripiprazole ranked among top evidence-supported options
38219278	2024	Systematic Review / Meta-Analysis	Neuropsychopharmacology Reports	Systematic review and NMA comparing brexpiprazole vs aripiprazole vs placebo in Japanese MDD patients with inadequate antidepressant response — directly applicable to East Asian populations
35510505	2023	Systematic Review / Meta-Analysis	Psychological Medicine	Comprehensive meta-analysis of antipsychotics as monotherapy and adjunctive therapy in MDD; most complete comparative effectiveness summary for the drug class
34167174	2021	Systematic Review / Meta-Analysis	Prim Care Companion CNS Disord	Long-term (≥6 months) efficacy and tolerability of adjunctive aripiprazole in MDD; remission as primary outcome — key data for maintenance treatment planning
37149344	2023	Narrative Review	Psychiatr Clin N Am	Pharmacotherapy review for TRD; identifies aripiprazole as the most widely studied augmentation agent with the strongest evidence base among atypical antipsychotics
36855876	2023	Narrative Review	Am J Psychiatry	Positions antipsychotics including aripiprazole in the evolving TRD therapeutic landscape; addresses use alongside esketamine and other emerging therapies
36239033	2023	Randomized Controlled Trial	J Psychopharmacol	Double-blind, placebo-controlled RCT; efficacy of adjunctive aripiprazole in MDD with somatic symptoms, with both clinical rating scale and EEG biomarker evidence
37815563	2023	Review	JAMA	JAMA comprehensive review of bipolar disorder diagnosis and treatment; contextualizes aripiprazole’s role across the full mood disorder spectrum including bipolar depression
21254788	2011	Clinical Overview	CNS Drugs	Seminal review of aripiprazole as adjunctive therapy in MDD; articulates the pharmacological rationale (D2/D3 partial agonism, 5-HT1A partial agonism, 5-HT2A antagonism) and synthesizes the pivotal trial program

Safety Considerations

Formal Taiwan package insert data is not available in this Evidence Pack (this is a Blocking data gap requiring resolution before regulatory submission). Based on the extensive Phase 3 and Phase 4 clinical trial record, the following considerations apply:

Key clinical risks: Akathisia (restlessness) is the most frequently reported adverse effect in MDD augmentation trials and may be misidentified as worsening anxiety; dose reduction or discontinuation resolves this
Metabolic effects: Weight gain, hyperglycemia, and dyslipidemia have been reported, necessitating baseline and periodic monitoring of body weight, fasting glucose, and lipid profiles
Impulse control disorders: Case series and pharmacovigilance data document aripiprazole-associated compulsive behaviors (gambling, hypersexuality, binge eating) attributable to D2/D3 partial agonism in reward circuits; patients should be counseled and monitored
Extrapyramidal symptoms: Risk is lower than first-generation antipsychotics, but tardive dyskinesia risk with long-term use cannot be excluded
Drug interactions: As a CYP2D6 and CYP3A4 substrate, dose adjustment is required with strong inhibitors (e.g., fluoxetine, paroxetine, ketoconazole) or inducers (e.g., carbamazepine); formal DDI data was not found in this query but interaction risk is clinically significant given typical co-prescription with antidepressants

Please obtain and review the full Taiwan package insert for the complete warnings, contraindications, and prescribing guidance.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Aripiprazole possesses L1-grade evidence for major affective disorder — multiple large Phase 3 double-blind placebo-controlled trials confirm statistically significant efficacy as adjunctive treatment in MDD, US FDA approval is already established for this indication, and a Taiwan Phase 4 real-world study (NCT01429831, n=300) further validates effectiveness in the local population. The TxGNN prediction score of 99.62% is fully corroborated by the clinical evidence base. The primary barrier to deployment in Taiwan is not efficacy uncertainty but rather the absence of local registration.

To proceed, the following is needed:

Immediate (Blocking): Obtain Taiwan TFDA package insert and conduct formal safety assessment — this is required before any clinical or regulatory action
Regulatory pathway: Confirm whether aripiprazole has an active TFDA registration application in progress or requires a new NDA submission; reference the Taiwan Phase 4 study data (NCT01429831) to support a local dossier
Subgroup definition: Identify the target patient profile for Taiwan deployment — Phase 3 evidence is strongest for SSRI/SNRI partial responders with ≥1 prior inadequate antidepressant trial; align with local psychiatry guideline thresholds for “treatment-resistant”
Comparative positioning: With the Phase 3 trial NCT07153406 comparing aripiprazole vs esketamine in elderly TRD pending, monitor results to determine whether aripiprazole remains preferred in the elderly subgroup or requires repositioning
Pharmacoeconomic analysis: Conduct Taiwan-specific cost-effectiveness analysis comparing aripiprazole augmentation to other available options (lithium augmentation, quetiapine, brexpiprazole) given formulary and reimbursement considerations
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.